What the studies show
Deaths from any cause were numerically lower but the difference was not statistically significant.
“All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80-1·01; p=0·067).”
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.Lancet, 20199,901 participants; median 5.4 years; HR 0.88.
In context
Dulaglutide is a once-weekly GLP-1 receptor agonist made of two GLP-1 analogue chains fused to an antibody fragment, approved for type 2 diabetes since 2014. In the 9,901-person REWIND trial it reduced major cardiovascular events by 12% relative to placebo over 5.4 years in people with diabetes, most of whom had no prior heart disease. It is not approved for weight management and produces modest weight loss — a few kilograms — well below semaglutide or tirzepatide. It is prescription-only everywhere it is sold.
Dulaglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Dulaglutide proven to help with all-cause mortality?
What studies are behind the grade?
Is Dulaglutide approved for this?
Other outcomes for Dulaglutide
- AMajor cardiovascular events (type 2 diabetes)1 large RCT (n=9,901, median 5.4 yr)
- ABlood glucose (HbA1c)AWARD programme (10+ RCTs)
- ABody weightAWARD programme
- AGastrointestinal adverse effectsadverseREWIND
Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →